Drug Trial Radar · NCT07519278
Bioequivalence Study of Pramipexole Dihydrochloride Extended-release Tablets in Healthy Chinese Subjects
Last checked: Nov 19, 2026Latest source record: Apr 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
49
Actual
Start
Mar 16, 2017
Primary completion
Apr 11, 2017
Study completion Feb 12, 2018
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study compared pramipexole dihydrochloride extended-release tablets (Test formulation) by Haisco Pharmaceutical Group Co., Ltd. with the reference formulation (MIRAPEX ER®,Boehringer Ingelheim GmbH of Germany) to evaluate the bioequivalence of single dose in Chinese healthy subjects under fasting and fed conditions.
Conditions
- Healthy
Interventions
Test formulation(pramipexole dihydrochloride extended-release tablets)Drug
Test formulation (pramipexole dihydrochloride extended-release tablets, Haisco Pharmaceutical Group Co., Ltd), A single oral dose of 0.375 mg, taken with 240mL of water
Reference formulation(MIRAPEX ER®)Drug
Reference formulation (pramipexole dihydrochloride extended-release tablets, Boehringer Ingelheim GmbH of Germany), A single oral dose of 0.375 mg, taken with 240mL of water
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax (Maximum Concentration)Time frame: From the start of administration to 72 hours post-dose
- AUC(0-t) (Area Under the Concentration-Time Curve from time 0 to time t)Time frame: From the start of administration to 72 hours post-dose
- AUC(0-∞) (Area Under the Concentration-Time Curve from time 0 to infinity)Time frame: From the start of administration to 72 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The General Hospital of Western Theater Command PLA
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.